hemodialysis patients. Cloudy (hemodialysis) (peritoneal) dialysis effluent
Conditions
Interventions
Intervention 1: During a 12-week intervention in hemodialysis patients, the intervention group received two synbiotic capsules daily, after lunch and dinner. Each synbiotic capsule (under the brand na
Bio Fermentation Company, Tehran, Iran) contains Lactobacillus rhamnosus, Lactobacillus casei, lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus fermentum, Lactobacillus plantarus and
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Perform HD treatment at least twice a week for a maximum of 4 hours each time Treatment under HD for at least 6 months No pregnancy or breastfeeding No immune system defects No history of active cancers No history of severe chronic diseases and acute medical conditions such as lung disease, cardiovascular disease, liver disease and acute pancreatitis No addiction to alcohol or drugs Lack of severe digestive disorders and diseases, HIV disease, mental problems Ability to drink at least 200 ml of water per day Life expectancy and survival for at least 3 months Confirmation of written consent
Exclusion criteria
Exclusion criteria: Patients with severe edema People who had infection 4 weeks ago People who took synbiotics, probiotics, prebiotics, or antibiotics during the 4 weeks before the study Candidates for kidney and organ transplantation or peritoneal dialysis during 3 months of study Taking immunosuppressive drugs or anticoagulants and chemotherapy drugs Sensitivity to complementary compounds The patient's unwillingness to participate in the study Lack of complete answers to questions Report side effects from taking synbiotics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma levels of advanced glycation end products in hemodialysis patients. Timepoint: First study (before the intervention) and end of the study (end of week 12). Method of measurement: Blood sample- Advanced Glycation End Products (AGE) ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma homocysteine levels in hemodialysis patients. Timepoint: Beginning of the study (before the intervention) and end of the study (end of week 12). Method of measurement: Blood sample - High performance liquid chromatography.;Plasma fibrinogen levels in hemodialysis patients. Timepoint: Beginning of the study (before the intervention) and end of the study (end of week 12). Method of measurement: Blood sample - coagulation factor.;Gastrointestinal function. Timepoint: Beginning of the study (before the intervention) and end of the study (end of week 12). Method of measurement: THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS).;Fasting blood sugar and HgA1C. Timepoint: Beginning of the study (before the intervention) and end of the study (end of week 12). Method of measurement: Blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadi Abdollahzad
Kermanshah University of Medical Sciences
Outcome results
None listed